Menu

  • Evolut™ built for a lifetime of care
  • Durability clinical data
  • Lifetime management options
  • Bicuspid valves
  • Get in touch

    • 2025 ESC/EACTS guidelines for the management of Valvular Heart Disease (VHD)1

    Aortic Stenosis (AS) key take-aways

    Age

    TAVI is recommended ≥70 years with tricuspid Aortic Stenosis (AS) if transfemoral feasible.

    Heart Team,
    lifetime management

    Decision based on clinical, anatomical & procedural factors, including lifetime management.

    Bicuspid Aortic valve stenosis

    TAVI may be considered at increased surgical risk and suitable anatomy.

    Learn more (open in new window)

    Design that delivers

    Icon 1
    Icon 1

    Supra-annular
    valve function

    Icon 1

    Conformable frame2

    Icon 1

    Radial
    force

    Icon 1

    Proven product &
    valve performance

    Evolut™ design differentiation is at the root of the valve performance and durability that has been proven in randomized clinical trials.3,4

    Explore our durability clinical data (open in new window)

    The future of TAVI

    Icon 1

    Pre-case
    planning

    Icon 1

    Options for
    access

    Icon 1

    Procedural
    excellence

    Icon 1

    Options for future
    intervention

    Medtronic’s latest innovation and CE marked indication offer a spectrum of options for patient lifetime management, such as coronary access and redo-TAV.

    Discover our lifetime management options (open in new window)

    Bicuspid aortic stenosis

    Icon 1
    Icon 1

    Supra-annular
    valve function

    Icon 1

    Conformable frame2

    Icon 1

    Proven product &
    valve performance

    When treating younger severe aortic stenosis patients, you will encounter patients with a bicuspid valve more frequently.5

    Learn about bicuspid aortic stenosis (open in new window)

    Ready to talk with us?

    Fill the form below to contact our team!

    *Indicates Required Field

    Your information will be processed and protected in accordance with our privacy statement

    Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

    You can always change your preferences or update your personal details by visiting the Preference center.

    See the Preference center

    1. Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. Published online August 29, 2025. doi:10.1093/eurheartj/ehaf194

    2. Puri R, et al. J Soc Cardiovasc Angiogr Interv. 2024;4:102448.

    3. Herrmann H. Two-Year Outcomes of the Five-Year SMART Trial; presented at CRT 2025.

    4. Forrest JK, et al. J Am Coll Cardiol. 2025:S0735-1097(25)05335-5

    5 F. Vincent, J. Ternacle, T. Denimal, et al. Transcatheter aortic valve replacement in bicuspid aortic valve stenosis Circulation, 143 (2021), pp. 1043-1061